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Abstract. The lysosomal protease Cathepsin D (CD) has been implicated in the homeostasis of lymphatic tissues. We investigated
whether the level of CD expression influences the progression and the clinical outcome in Non-Hodgkin’s Lymphomas (NHLs).
The expression of CD was assessed by immunohistochemistry and immunofluorescence in biopsies of Diffuse Large B Cell
Lymphomas (DLBCL, 35 cases), Follicular Lymphomas (FL, 9 cases of grade I-II plus 14 cases of grade IIIB), Chronic
Lymphocytic Leukaemias (CLL, 17 cases) and Peripheral T-cell Lymphomas (PTCL, 5 cases). CD staining showed a cytoplasmic
punctate pattern compatible with its lysosomal localization. Based on the level of CD expression and the proportion of positive
cells, lymphomas were classified as ‘low expressing’ (< 20% of tumor cells) or ‘highly expressing’ ( 20% of tumor cells).
Lymphomas highly expressing CD were associated with a worse stage (III-IV) at diagnosis (31/34 cases; p = 0.002) and with
a poor clinical outcome (i.e., partial remission and death; 28/34 cases; p = 0.03). In the subgroup of aggressive/high grade
of malignancy lymphomas (i.e., DLBCL, FL IIIB and PTCL), the Kaplan-Meier curve revealed a very low cumulative overall
survival probability (∼20% at 5 year) for patients bearing a NHL with > 40% CD-positive cells compared to that of patients
bearing a NHL with < 20% CD-positive cells (∼70% at 5 year). This correlation was statistically significant (log-rank test, p =
0.01). In Cox multivariate analysis CD failed to be a prognosticator independent of pathologic stage, though the hazard ratio
confirmed the association of low expression with a better survival probability. These data indicate that the presence of a high
percentage of CD-positive tumor cells negatively reflects on the progression of NHLs.
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1. Introduction
Non-Hodgkin’s Lymphomas (NHLs) encompass
malignant lymphoproliferative disorders that originate
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from B or T-lymphocytes (and rarely form Natural
Killer cells), and that are heterogeneous for morphol-
ogy, immunophenotipic and cytogenetic profiles, and
biological characteristics. On the basis of the clinical
presentation and the patient’s life expectancy, oncol-
ogists categorize NHLs in ‘aggressive’ or ‘indolent’
lymphomas, which correspond to the intermediate/high
grade of malignancy and low grade of malignancy sub-
groups, respectively (reviewed in 1,2). Beside the five
factors of the International Prognostic Index (age,stage,
serum LDH, performance status and number of extra-
nodal sites) commonly used, the gene expression sig-
nature of the NHL greatly concurs to better assess the
prognostic profile of the patient. Accordingly, a wide
range of proteins that monitor or directly control cell
proliferation, cell differentiation or cell death (e.g., bcl-
6, bcl-2, p53, Ki-67, nm-23, c-FLIP and survivin) have
been proposed as prognostic markers in NHLs [3–9].
Cathepsin D (CD) is a lysosomal aspartic protease
ubiquitously expressed in human tissues, in which it
can be present under three molecular forms: the precur-
sor (enzymatically inactive), the intermediate single-
chain and the mature double-chain polypeptides (both
the latter are enzymatically active). CD was shown
of vital importance for cell survival and tissue home-
ostasis, as deduced from the phenotype of mice ho-
mozygously knocked-out for CD [10]. These mice are
not vital beyond the third-fourth week after birth and
show atrophy of primary lymphoid organs, intestine and
heart [10]. CD has been shown to play an active role in
the apoptotic response of cancer cells to chemotherapy
drugs [11–14] or death-inducing cytokines [15,16], fol-
lowing its translocation into the cytosol. The precursor
of CD, which is highly secreted by cancer cells, has
been shown to stimulate the growth and the activation
of peripheral human lymphocytes [17,18]. The regula-
tory function of CD in cell proliferation and apoptosis
in lymphoid tissues potentially implicates this molecule
in the pathogenesis and progression of NHLs. To test
this hypothesis, we assessed the expression of CD in
NHL tumor cells and searched for possible correlations
between the proportion of CD-positive lymphoma cells
and the clinico-pathological parameters at diagnosis
and the response to therapy. CD expression was ana-
lyzed by immunohistochemistry (IHC) and immunoflu-
orescence (IF) in a wide series of NHLs, which in-
cluded 54 cases classified as ‘aggressive’ or high grade
of malignancy and 26 cases classified as ‘indolent’ or
low grade of malignancy. Our findings indicate that
the presence of a high percentage of CD-positive tu-
mor cells negatively reflects on the clinical response to
chemotherapy of NHLs.
2. Materials and methods
2.1. Patient cases and histological diagnosis
A series of paraffin-embedded biopsies was selected
in the years 2000–2006 from the files of the Depart-
ment of Pathology of Universita` del Piemonte Orien-
tale (Novara, Italy). This included the following his-
tologic types classified according to the current WHO
Classification of Lymphoid Neoplasms [19]: 35 Dif-
fuse Large B-Cell Lymphomas (DLBCL), 23 Follicular
(center) Lymphomas (FL), 17 B-cells Chronic Lympho-
cytic Leukaemia (CLL) and 5 Peripheral T-cell Lym-
phomas (PTCL). Routine immunophenotyping with a
panel of antibodies corroborated the histological diag-
nosis.
All patients were subjected to chemotherapy and/or
radiotherapy, following standard criteria based on clin-
ical stage, histologic type and patient performance sta-
tus. The study was conducted in conformity of the rules
currently approved by the local ethic committee.
2.2. Immunohistochemistry and Immunofluorescence
Immunohistological analysis was performed inde-
pendently by four investigators (GV and SK for IHC;
CI and GN for IF) on biopsies obtained prior to any
therapy. Formalin-fixed paraffin-embedded tissue sec-
tions were cut from all NHL cases. IHC was performed
using a standard procedure as previously described in
details [7]. CD was revealed by incubating the sec-
tions for 30 min with a mouse monoclonal antibody
(diluted 1: 500; clone BC011) purchased from Cal-
biochem (San Francisco, CA). After washing out the
unbound antibody, the sections were further incubat-
ed for 30 min with a peroxidase-conjugated polymer
carrying an antibody against mouse immunoglobulins
(ChemMate DAKO EnVision kit; DAKO Cytomation
Glostrup, Denmark). After washing out the excess of
antibody, a reaction product was developed by us-
ing the ChemMate Diaminobenzidine as chromogen
(DAKO Cytomation). Negative control was made either
by omitting the primary antibody and by using in the
first step an isotype matched polyclonal antibody spe-
cific for HBcAg (Dako; diluted 1:200) (not shown). Fi-
nally, the sections were counterstained with hemalume
(Merck, Germany). Non neoplastic cells were exclud-
ed from the evaluation. Macrophages were identified
by staining with an anti-CD68 monoclonal antibody
(Dako).
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Representative areas were imaged using a micro-
scope (Leitz Diaplan, Germany ) equipped with a dig-
ital camera. The number of CD-positive tumor cells
was evaluated by manual counting, in agreement with
criteria well established in the pathologists community.
At least 10 fields for each case were considered. The
cells were judged as positive when the reaction product
was well detectable at low magnification.
For IF staining, the sections (prepared as above) were
incubated first with the primary antibody (1: 100 in
phosphate buffer saline supplemented with 0,1% Tri-
ton X-100 and 4% Fetal Calf Serum, for 16 h in a
humid chamber at 4◦C) and then with Texas Red- or
FITC-conjugated secondary antibodies (diluted 1:200
as above, for 1 h at room temperature in a humid cham-
ber). Excess of unbound antibody was removed at each
step by two washes with phosphate buffer saline. As
negative control, the primary antibody was omitted and
the sections were incubated only with the secondary
antibody. The nucleus was evidenced by staining the
chromatin with the fluorescent dye Propidium Iodide
(PI), as previously reported [7]. Stained sections were
mounted with Slow-FAD (Light AntiFADE kit, Molec-
ular Probes) and observed under a laser confocal im-
munofluorescence microscope (Leica Fluorescent Mi-
croscopy DMI600, Heidelberg, Germany). Each biop-
sy was tested at least three times. At least four fields per
section were imaged and evaluated by manual count-
ing. Macrophages, which expressed CD at high lev-
el, were identified by double-staining with both anti-
CD and anti-CD68 monoclonal antibody (Dako) and
excluded from evaluation. Representative images are
shown.
2.3. Western blotting
Pieces from frozen biopsy were cut and finely ho-
mogenized by several cycles of freeze-thawing and
sonication in a phosphate buffer containing detergents
(Triton X-100 and Na-deoxycholate) and a cocktail of
protease inhibitors. A 50 µg of protein homogenate
was resolved by SDS-polyacrylamide (13.5%) gel elec-
trophoresis under reducing conditions. Electrotrans-
fer and immunodetection were carried out as previ-
ously described [14]. CD polypeptides were detected
with the same monoclonal antibody used for IHC and
IF (Calbiochem, San Francisco, CA). Immunocom-
plexes were revealed by incubation with peroxidase-
conjugated goat-anti-mouse antibody (1:20.000) and
subsequent peroxidase-induced chemiluminescence re-
action (Biorad, Hercules, CA, USA).
2.4. Statistical analysis
Data were statistically analysed with the Microsoft
Excel XLStat 2008 software to calculate the Odds Ratio
(O.R.) and to perform the Chi-square test. The Fisher’s
exact test was also employed for pair wise comparison
of distributions of categorized groups. The probabili-
ty of overall survival (OS) for patients was estimated
by the Kaplan-Meier method [20]. OS was calculated
from the date of initial diagnosis until the date of last
follow-up or patient’s death. Surviving patients were
censored at the date of last contact and mathematically
removed from the curve. Patients who died were cen-
sored at the date of death. The significance of differ-
ences between survival curves was calculated by using
the log-rank test. To determine the relative influence of
CD and of pathologic stage on OS, univariate and mul-
tivariate analyses were also performed using the Cox
proportional hazard model [21]. These analyses yield-
ed the chi-square, hazard ratios, the confidential inter-
vals and p values. To indicate statistical significance the
threshold for p values was taken at 5% level. Statistics
was performed using the XL-STAT 2010 software.
3. Results
3.1. Patients’ clinical parameters
The relevant clinical data of the patients diagnosed
with NHL included in the present study are reported
in Table 1. The following information were available:
clinical stage at first diagnosis, histological type, ob-
jective response to chemo- and radiotherapy, and clini-
cal outcome. On pathologic bases, the histologic types
belonged to a subgroup classified as NHLs of inter-
mediate/high grade of malignancy and to a subgroup
classified as NHLs of low grade of malignancy. The
first subgroup encompassed DLBCL, FL of grade IIIB
(showing a higher proportion of centroblasts and a par-
tially diffuse pattern) and PTCL. These neoplasms are
characterized by an aggressive clinical behaviour (re-
viewed in 2). The second subgroup encompassed CLL
and FL of grade I and II. These neoplasms show an
indolent clinical behavior (reviewed in 1). Response
to therapy regimen was evaluated according to the in-
ternational guidelines. Clinical outcomes were classi-
fied as complete remission (CR, disappearance of any
evidence of disease for at least 24 months), partial re-
mission (PR, =/> 50% decrease of tumor lesions for
at least 24 months) and exitus (DdD, Death due to the
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Table 1
Clinical characteristics of NHL cases. Data set of NHL patients included in the present study. Abbreviations used
are: CLL, Chronic Lymphocytic Leukaemia; DLBCL, diffuse large B-cell lymphoma; FL, Follicular Lymphomas;
PTCL, Peripheral T-cell Lymphomas. Pathological staging (∗one lacking data) and clinical outcome are indicated.
CR, Complete Remission.
Histologic type Sex n. cases age (range) Median age Stage CR rate Survival rate (5y)
I-II III-IV
DLBCL (35) m 19 44–78 67 14* 20 43% 60%
f 16 27–81 73
FL I-II (9) m 1 69 63 2 7 22% 77%
f 8 48–73
FL IIIB (14) m 6 35–75 62 5 9 50% 86%
f 8 49–79 73
CLL (17) m 9 34–81 69 1 16 12% 76%
f 8 66–85
PTCL (5) m 3 49–73 68 0 5 0% 0%
f 2 73–74 73.5
Disease). Poor clinical outcome included no response
at all (progression and exitus) or only partial response
to therapy (PR). The survival rate was calculated at
5 years post-diagnosis.
3.2. Cathepsin D expression in tumor cells of NHL
tissue sections
The expression of CD was analyzed by IHC and by
IF in biopsy sections obtained from patients diagnosed
for NHL and not yet subjected to therapy. Results from
both techniques overlapped, though some cases judged
negative on IHC appeared faintly positive on IF owing
to the highest sensitivity of the latter technique. Repre-
sentative images of CD expression and cellular distri-
bution, as assessed by IHC and IF in selected cases, are
shown in Figs 1 and 2, respectively. CD was detected
in the cytoplasm of neoplastic cells. At high magnifi-
cation, CD positivity appeared as distinct spots in the
cytoplasm, a pattern consistent with its intra-lysosomal
localization. The nuclei of tumor cells were constant-
ly negative for CD. In most of the cases, CD-positive
spots appeared thoroughly distributed in the cytoplasm,
whereas in few other cases the reaction product ap-
peared localized in a small cytoplasmic area proximal
to the nucleus. Macrophages infiltrating the tumor tis-
sue were strongly positive for CD. These cells, easily
recognizable on the basis of their morphology and di-
mension, were identified as CD68 positive. Apoptotic
cells within the tumor context were recognized on the
basis of chromatin condensation and fragmentation, as
evidenced by PI staining (see inset in Fig. 2).
In order to validate the specificity of the anti-CD an-
tibody, we analyzed by western blotting the molecular
forms of CD expressed by tumor cells. The analysis
was performed in 20 cases, for which a frozen biopsy
was available. A selection of these cases, representa-
tive of different levels of CD expression, is shown in
Fig. 3. Specific bands revealed by the antibody corre-
spond to the following molecular forms of CD: i) the
precursor (P), enzymatically inactive, of ∼53 kDa; ii)
the intermediate single-chain (I) of ∼48 kDa; and iii)
the large-chain of the mature (M, ∼31 kDa) double-
chain. The latter is by far the most represented molec-
ular form in all samples. In some cases, the large-chain
of the double-chain form appears as a doublet (of 33 and
31 kDa), likely representing micro-heterogeneities gen-
erated by aminoacid trimming within the lysosomes.
CD expression was evaluated semiquantitatively by
IHC in all samples. Only tumor cells were considered.
CD-positive macrophages, recognized by morphology
and by their CD68 positivity, were excluded from the
counting. Based on the proportion of CD-positive cells
within the tumor tissue, the extent of CD expression
was initially stratified into four ranges of positivity: 0
to 10%; 10 to 20%; 20 to 40% and more than 40%.
Negative expression, that is a basal expression faintly
detectable or under the detection limit of the method,
was classified as < 10%. More than 50% of the tumors
fell into the 0-20% range of expression (Table 2A). The
final threshold was set at 20% CD-positive cells. The
percentage of CD-positive tumor cells in the various
NHL histologic types examined is reported in Table 2B.
Altogether, 46 tumors showed a low percentage (<
20%) of cells over-expressing CD and 34 tumors were
characterized by a high ( 20%) percentage of pos-
itive cells. No statistically significant correlation was
found between the extent of CD expressing cells and
the histologic type. We note, however, that the large
majority of DLBCL (27/35) were characterized by a
low proportion of cells positive for CD. When tumors
were categorized for pathological malignancy, it was
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Fig. 1. Cathepsin D immunohistochemical expression in tissue sections of NHLs. IHC images refer to representative fields of selected cases of
different histologic types. Acronymus for NHL histologic types as follow: DLBCL, Diffuse Large B Cell Lymphoma; FL, Follicular Lymphoma;
CLL, Chronic Lymphocytic Leukaemia. The reaction product, indicative of positivity, show a punctate pattern scattered in the cytoplasm of
tumor cells. The Cathepsin D (CD) expression score assigned to the case is reported. The inset in panel D at higher magnification shows the
punctate staining of CD, indicative of lysosomal localization. Original magnification: 440x in panels A, B, C, E, F and 220x in panel D).
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Fig. 2. Immunofluorescence staining of Cathepsin D in tissue sections of NHLs. Immunofluorescence staining of CD and propidium iodide
(PI) counter-staining of nuclei of NHL sections. Acronymus for NHL histologic type as follow: DLBCL, Diffuse Large B Cell Lymphoma;
FL, Follicular Lymphoma; CLL, Chronic Lymphocytic Leukaemia, PTCL, Peripheral T Cell Lymphoma. The proportion of CD-positive cells is
indicated. The arrows point to macrophages highly expressing CD. The punctate pattern of CD staining can be appreciated in panel F. Panels G
and H show examples of apoptotic cells with condensed and fragmented chromatin, as stained by PI. Scale bar = 20 µm.
found that approximately one-third of the high-grade
(Hg) of malignancy subgroup and two-third of the low-
grade (Lg) of malignancy subgroup presented with a
high proportion of CD-positive cells (Table 2C).
3.3. Correlation of CD expression with
clinico-pathological parameters at diagnosis and
clinical outcome
We asked about the biological significance of our
finding and investigated whether the level of CD ex-
pression reflected on clinico-pathological features of
NHLs. First, we checked for any correlation with the
pathological stage at diagnosis (Table 3A). Strikingly,
31 out of 34 (91%) NHLs expressing a high percentage
of CD-positive cells were diagnosed at stages III and IV
(O.R. = 7; p = 0.002). When aggressive (high grade
of malignancy, Hg-NHL) and indolent (low grade of
malignancy, Lg-NHL) subgroups of NHLs were con-
sidered separately, only the former subgroup showed
a statistically significant correlation (O.R. = 16; p =
0.005) between CD expression and pathological stag-
ing (Tables 3B–C).
Next, we performed a statistical analysis to correlate
the IHC data with the clinical outcome. From the data
reported in Table 4, we note that NHLs highly express-
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Fig. 3. Western blotting analysis of cathepsin D expression. Representative western blotting of CD in DLBCL and CLL expressing different
proportion of CD-positive cells within the tumor context. The level of CD expression as assessed by IHC is reported. Based on IHC, samples 3
and 4 presented macrophage infiltration amounting to 5% and 8%, respectively. Molecular forms of CD: P, precursor (∼53 kDa); I, intermediate
single-chain (∼48 kDa); M, large-chain (∼31 and 33 kDa) of the mature double-chain. The blot was stripped and re-probed for actin as marker
for control loading of tissue proteins in the lanes. Data on CD expression as assessed by IHC and clinical outcome of the tumor analyzed are also
reported (abbreviations as in Tables 1 and 3).
ing CD associated with a poor clinical outcome of pa-
tients (p = 0.03). In this group, only 6 patients (17.6%)
underwent complete remission (CR), whereas in the
group of patients bearing a NHL with a low positivity
for CD as many as 20 out of 46 (43.5%) underwent CR.
These correlations were statistically significant (p =
0.05) also when clinical outcome was considered sep-
arately as CR, PR and Death-due-to-Disease (DdD).
The aggressive and indolent subgroups of NHLs were
then considered separately (Tables 5A–B). Both in the
two subgroups, only 3 patients out 17 bearing a NHL
highly expressing CD experienced a CR. However, it
was found that only in the subgroup of aggressive his-
tologic types the correlation between the percentage of
CD-positive tumor cells and the clinical outcome was
statistically significant (p = 0.04).
We further investigated whether in the Hg-malign-
ancy subgroup of NHLs the expression of CD could be
of prognostic significance. To address this point, we
estimated the overall survival (OS) probability of NHL
patients by the Kaplan-Meier method. Figure 4 shows
the OS Kaplan-Meier curves relative to the group of
patients bearing an aggressive, Hg-NHL. Log-rank test
was applied to test the statistical significance of such
correlation. Patients bearing a Hg-NHL that expresses
a low percentage (< 20%) of CD-positive cells showed
a∼72% OS at 5-year, regardless of the NHL histologic
type (Fig. 4). By contrast, Hg-NHLs highly expressing
CD ( 20% of CD-positive cells) associated with a low
probability of OS of patients. In particular, in these pa-
tients the 5-year OS probability was ∼34% (Fig. 4A).
Statistical significance determined by the log-rank test
was p = 0.06. To see whether OS probability was re-
lated to the proportion of CD-positive cells within the
tumor, we reconsidered the stratification of CD expres-
sion in the Hg-NHLs highly expressing CD setting the
cut-off at > 40%. No one of the patients bearing a NHL
with such a high proportion of CD-positive cells under-
went CR. We calculated the Kaplan-Meyer curve for
these patients (i.e., bearing a NHL with > 40% CD-
positive tumor cells) in comparison with patients bear-
ing a NHL expressing a low percentage (< 20%) of CD-
positive cells (Fig. 4B). Patients bearing a very-high
CD-expressing Hg-NHL (n = 11) revealed at 5 year
an OS probability of ∼20%. In this case, log-rank test
indicated that the different OS probability among the
two groups of patients was statistically significant (p =
0.01; Fig. 4B). To see whether the correlation between
CD expression and OS was associated with individual
histologic subtypes the univariate Kaplan-Meier anal-
ysis was applied to DLBCL, the most represented lym-
phoma in our series. At 5 years, patients (n = 27)
whose tumor contained less than 20% of CD-positive
cells showed an OS probability of 65%, whereas the
patients (n = 8) whose tumor contained  20% CD-
positive cells showed an OS probability of 20% (data
not shown). However, owing to the small numbers,
the difference in OS between groups did not reach the
statistical significance (log-rank test, p = 0.23).
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Table 2
Cathepsin D (CD) expression in NHLs. The number of CD-positive tumor cells were evaluated
by immunohistochemistry in serial sections from NHL tissues (see Fig. 1) and the score was
assigned as explained in Materials and Methods. A) Stratification of CD positivity in the high-
grade (Hg) and Low-grade (Lg) of malignancy sub-groups of NHLs. B) CD positivity in the
various histologic types of NHLs examined. Abbreviations used as described in the legend to




3.4. Overall survival as influenced by Cathepsin D
expression and pathologic stage in multivariate
analysis
As predictable, inferior pathologic stage was asso-
ciated with better clinical outcome (Table 6). Of the
22 patients with NHL staged I-II, only 3 died (∼14%)
and as many as 14 (∼64%) underwent CR; whereas,
of the 57 patients with NHLs staged III-IV, 23 died
(∼40%) and only 12 (∼21%) underwent CR. Similarly,
of 19 patients with Hg-NHL staged I-II, only 3 died
(∼16%) and 13 (∼68%) underwent CR; whereas, of
the 34 patients with Hg-NHL staged III-IV, 17 died
(50%) and only 9 (∼26%) underwent CR. We then
calculated the OS probability with the Kaplan-Meier
method in the groups of patients staged I-II and III-
IV. In the whole series, the OS probability of patients
staged I-II (n = 22) and of those staged III-IV (n =
57) were ∼88% and ∼42%, respectively (curves not
shown ) (log-rank test, p = 0.021). In the Hg-NHL
series, the OS probability of patients staged I-II (n =
19) and of those staged III-IV (n = 34) were ∼85%
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Table 3
Correlation between the level of Cathepsin D expression and pathological staging. Statistical correlation
between the proportion of Cathepsin D-positive cells in NHL and the pathologic stage at presentation.
In the whole series (panel A), Fisher exact test indicated that NHL with > 20% of CD-positive cells
statistically associated with stages III-IV at diagnosis (p = 0.001). Panels B and C refer to the subgroups





and ∼45%, respectively (Fig. 5A) (log-rank test, p =
0.014). Of the 34 patients with a Hg-NHL staged III-
IV, 18 were bearing a tumor with < 20% CD-positive
cells (10 survivors plus 8 DdD) and 16 were bearing a
tumor with  20% CD-positive cells (7 survivors plus
9 DdD). The Kaplan-Meier OS curves of these patients
(Fig. 5B) revealed a lower OS probability for the high
CD-expressing group (p = 0.78).
Above data revealed that Hg-NHLs with a high pro-
portion of CD-positive cells were linked to a high
pathologic stage at diagnosis (Table 3) and to poor OS
(Fig. 4). To determine whether the prognostic value of
CD persisted even when also the pathologic stage was
considered, we performed a multivariate analysis of OS
using the Cox proportional hazards model. The uni-
variate analysis for CD expression and stage shown in
Table 7A confirmed the prognostic value of CD expres-
sion in Hg-NHLs (p = 0.07 with cut-off = 20%; p =
0.03 with cut-off = 40%) and of the pathologic stage in
the whole series (p = 0.03) and in the Hg-NHLs sub-
group (p = 0.02). We then carried out the Cox multiple
regression to test the prognostic value of CD expression
adjusting for pathologic stage. Statistical data reported
in Table 7B indicate that the pathologic stage is an in-
dependent parameter significantly correlated with OS
in the whole series of NHLs (p = 0.02), whereas in the
Hg-NHLs sub-group the p value does not reach the sta-
tistical significance (p = 0.07). In the whole series of
NHLs, CD expression was not significantly correlated
with OS (p = 0.32), as expected. In the Hg-NHLs sub-
group, because of the small numbers, CD failed to be
significantly associated to OS as an independent prog-
nosticator, still the hazard ratio yielded confirmed that
tumors low expressing CD (adjusted for the stage) were
associated to a higher probability of survival compared
to those highly expressing CD.
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Table 4
Correlation between the level of Cathepsin D expression and clinical outcome. Sta-
tistical correlation between the proportion of Cathepsin D-positive cells in NHL and
the clinical outcome (CR, complete remission; PR, partial remission; DdD, death-due-
to-disease; other = PR plus DdD). Statistics was calculated for CR vs. poor outcome
assumed as PR + DdD (upper panel) or PR and DdD separately (lower panel). Chi-
square test indicated a statistically significance correlation between tumors expressing
 20% CD-positive cells and a poor prognosis.
4. Discussion
As in other tissues, homeostasis in the lymphoid tis-
sue is strictly dependent on the balance between cell
proliferation and apoptotic cell death. The lysosomal
protease CD has been implicated in the control of both
these events. In these respect, it is worth noting that
mice homozigous knocked-out for CD present with at-
rophy of lymphoid organs [10]. Moreover, the secreted
precursor of CD has been shown to activate and stimu-
late the growth of peripheral human lymphocytes [17,
18]. Thus, the potential regulatory function of CD in
cell proliferation and apoptosis in lymphoid tissues may
implicate this molecule in the pathogenesis and pro-
gression NHLs. Previous reports outlined the potential
of CD as a biomarker of tumor progression in various
epithelial cancers [22–30]. We interrogated on the po-
tential prognostic value of CD in lymphomas. To this
end, we have studied the expression of CD in a series
of different NHL histologic types and searched for any
correlation between the extent of CD-positive tumor
cells and the clinico-pathological parameters and pa-
tient’s clinical outcome after therapy. CD expression
was assessed by IHC and IF on biopsy specimes ob-
tained from patients prior to any treatment. CD staining
in NHL tumor cells showed a punctate pattern, which
is compatible with its confinement within lysosomes.
Western blotting analysis validated the specificity of
the antibody and also the staining assessment of CD
expression. Western blotting analysis revealed that the
mature double-chain form, which is resident within
lysosomes, is the main CD molecular form expressed
in NHLs, regardless of the histotype and of clinical fea-
tures. The literature gives no uniform recommendation
for a cut off point of CD expressed as percentage of tu-
mor cells positive in IHC. In esophageal squamous cell
carcinomas, it was found that > 10% of CD-positive
cells significantly associated with cell proliferation, in-
vasive tumor growth and patient’s poor prognosis [28].
As no data are available for lymphomas, we initially
chose three different cut off values for CD expression,
namely > 10%,  20% (high expression) and  40%
(very high expression). The 20% threshold of CD ex-
pression discriminated in our series two different popu-
lations with differences in clinico-pathological charac-
teristics, prognosis and survival. In this view, we have
chosen 20% as the cut off value for the main statistical
analyses. It is to be stressed that in our study only tu-
mor cells were considered for CD expression. In fact,
stromal reactive cells (mainly macrophages) infiltrate
the tumor and clearly contribute to the actual level of
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Table 5
Correlation between the level of Cathepsin D expression and clinical outcome in ag-
gressive and indolent NHLs groups. Statistical correlation between the proportion of
Cathepsin D-positive cells in NHLs and the clinical outcome (CR, complete remission;
PR, partial remission; DdD, death-due-to-disease; other = PR plus DdD) in the sub-
groups of patients bearing high-grade of malignancy (Hg) or low-grade of malignancy
(Lg) NHLs (panels A and B, respectively). Statistics was calculated for CR vs. poor
outcome assumed as PR + DdD (upper panel) or PR and DdD separately (lower pan-
el). Chi-square test indicated a statistically significance correlation between tumours
expressing  20% CD-positive cells and a poor prognosis only in the subgroup of
patients bearing a Hg-NHL.
A
B
CD. This is of particular relevance, since it has recently
been reported that the expression of CD of macrophage
origin in DLBCL, assessed both by genome array and
IHC, is higher in tumors from patients considered cured
after primary chemotherapy compared to those from
patients showing chemoresistance [31].
We found that patients bearing a NHL with a high
percentage of CD-positive cells were more frequently
diagnosed at stage III or IV and experienced a poor
clinical outcome (PR or DdD). In this group, only 6 out
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A
B
Fig. 4. Kaplan-Meier curves of overall survival in Hg-NHL patients as a function of Cathepsin D expression. In A) comparison of OS in patients
bearing Hg-NHLs expressing a low (< 20%) and a high ( 20%) proportion of CD-positive tumor cells. Difference in OS probability is not
statistically significant (p = 0.06). In B) comparison of OS in patients bearing NHLs expressing a low (< 20%) and a very high ( 40%)
proportion of CD-positive tumor cells. Difference in OS probability is statistically significant (p = 0.01). p, statistical value for significance as
calculated by log-rank test. The number of patients per group is indicated.
of 34 patients underwent CR. Patient’s poor prognosis
in the group bearing a NHL with a high proportion (
20%) of CD-positive cells was not associated with a
particular histologic type (7 DLBCL, 8 FCL, 8 CLL
and 5 PTCL), nor with a specific therapy regimen (re-
gardless of whether this included or not rituximab).
On the whole, these data indicate that the probability
to experience a CR is much higher in patients bear-
ing a NHL with a low percentage of CD-positive cells
than in patients bearing a NHL with a high percentage
of CD-positive cells. When the aggressive (high grade
of malignancy) and indolent (low grade of malignan-
cy) NHLs were considered separately, only the former
subgroup of NHLs showed a statistically significant
correlation between CD expression and pathological
staging. In addition, as estimated by the Kaplan-Meyer
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Table 6
Correlation between the pathologic stage and clinical outcome in NHLs. Statistical correlation
between the pathologic stage and the clinical outcome in the whole series of NHLs (panel A)
and in the Hg-NHLs sub-group (panel B). Superior pathologic stage is significantly associated
with a low rate of CR and a high rate of death.
A
B
curves, the survival probability of Hg-NHL patients
was inversely related to the proportion of CD-positive
cells. In particular, patients bearing an Hg-NHL with >
40% of CD-positive cells showed a low OS probability
(∼20%) in comparison to that of patients bearing an
Hg-NHL expressing detectable CD in a low proportion
of tumor cells (∼70%). This difference was statistically
significant (log-rank test, p = 0.01). Pathologic stage
was also significantly correlated with OS, as expected.
Since a high proportion of CD-positive cells was also
associated with a worse staging at diagnosis, we ap-
plied the Cox regression model to assess the relative
prognostic significance of CD expression and of patho-
logic stage. Univariate analyses confirmed the prog-
nostic value of CD expression. Because the number
of patients very highly expressing CD was small in the
present study, CD could not be shown to be an indepen-
dent factor for OS in the multivariate analysis. How-
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A
B
Fig. 5. Kaplan-Meier curves of overall survival in Hg-NHL patients as a function of pathologic stage and Cathepsin D expression. In A)
comparison of OS in patients bearing Hg-NHLs staged as I-II (n = 19) or III-IV (n = 34) (one data lacking). Difference in OS probability
is statistically significant (p = 0.014). In B) comparison of OS in patients bearing NHLs staged III-IV and expressing a low (< 20%) or high
( 20%) proportion of CD-positive tumor cells. Difference in OS probability is not statistically significant (p = 0.783). p, statistical value for
significance as calculated by log-rank test. The number of patients per group is indicated.
ever, the hazard ratio indicated a better probability of
survival for patients bearing a tumor with < 20% CD-
positive cells. It is to note that of the 34 patients with
Hg-NHL staged III-IV, 18 were low-expressing and
showed an OS of 52% and 16 were highly-expressing
and showed an OS of 35% (p = 0.78). Though the
numbers were not sufficient for statistical significance,
the trend indicates that patients with Hg-NHLs staged
III-IV and highly expressing CD have a very low OS
probability. It can be hypothesized that, during progres-
sion of NHLs, the emergence of increased numbers of
CD-positive cells leads to a more aggressive clinical
course of the disease. This aggressiveness manifests
clinically with a worse staging at diagnosis and, later
on, with a failure of the chemotherapy treatments.
In the Lg-NHLs sub-group, two-third (17/26) of tu-
mors expressed CD in more than 20% of the cells and
the majority (15/17) of these tumors staged III-IV. Still,
CD expression showed no significant correlation with
clinico-pathological characteristics in this sub-group of
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Table 7
Cox regression analysis of survival as influenced by Cathepsin D expression and pathologic stage. The Cox
proportional hazard model was applied to determine the prognostic significance of Cathepsin D expression
and of pathologic stage in the whole series of NHLs and in the Hg-NHL sub-group. A) Univariate analysis
of CD expression (< 20% vs. 20% or 40%) and of pathologic stage (I–II vs. III–IV). B) Multivariate
analysis of CD expression adjusted for pathologic stage.
A
B
NHLs. We have not a clear explanation for this, though
one principal reason likely resides in the small number
of Lg-NHLs examined.
In conclusion, we have shown, for the first time,
that CD can be over-expressed by NHL cells and that
the presence of a high percentage of CD-positive tu-
mor cells negatively reflects on the clinical response
to chemotherapy and on the progression of NHLs. We
found that over-expression of CD in a large propor-
tion of tumor cells in Hg-NHL identifies a subgroup of
lymphomas with poor prognosis and short OS. Further
studies will be necessary to definitively assess whether
CD is indeed a reliable prognostic marker in NHLs. We
plan to extend our analysis to a larger cohort of NHL-
bearing patients with a number of indolent and aggres-
sive NHL histologic types sufficient to reach conclu-
sions statistically significant on the correlation between
CD expression and OS.
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